Literature DB >> 19698277

Severe community-acquired pneumonia and PIRO: a new paradigm of management.

Jordi Rello1, Thiago Lisboa, Richard Wunderink.   

Abstract

Appropriate antibiotic management and aggressive supportive therapy is not enough to improve survival in severe community-acquired pneumonia (sCAP), a systemic syndrome involving infectious organisms, inflammation, and coagulation systems. A sepsis severity staging system focused on predisposition, insult, deleterious response, and organ failure (PIRO) provides a useful basis for risk stratification and therapy. A new paradigm of management is suggested based on early identification of patients at risk, aggressive management, modulation of host response, and need for adjunctive therapy. The CAP-PIRO score is a new, simple tool stratifying patients in four categories and may be useful for early identification of patients who may benefit from adjunctive therapy.

Entities:  

Year:  2009        PMID: 19698277     DOI: 10.1007/s11908-009-0049-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  39 in total

1.  Evaluation of ICU admission criteria and diagnostic methods for patients with severe community-acquired pneumonia: current practice survey.

Authors:  Marcos I Restrepo; Thomas Bienen; Eric M Mortensen; Antonio Anzueto; Mark L Metersky; Patricio Escalante; Richard G Wunderink; Bonita T Mangura
Journal:  Chest       Date:  2008-03       Impact factor: 9.410

2.  The ventilator-associated pneumonia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia.

Authors:  Thiago Lisboa; Emili Diaz; Marcio Sa-Borges; Antonia Socias; Jordi Sole-Violan; Alejandro Rodríguez; Jordi Rello
Journal:  Chest       Date:  2008-09-08       Impact factor: 9.410

3.  Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?

Authors:  Angel Vila-Corcoles
Journal:  Lancet Infect Dis       Date:  2008-07       Impact factor: 25.071

4.  A prediction rule to identify low-risk patients with community-acquired pneumonia.

Authors:  M J Fine; T E Auble; D M Yealy; B H Hanusa; L A Weissfeld; D E Singer; C M Coley; T J Marrie; W N Kapoor
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

5.  Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.

Authors:  M I Restrepo; E M Mortensen; G W Waterer; R G Wunderink; J J Coalson; A Anzueto
Journal:  Eur Respir J       Date:  2008-09-03       Impact factor: 16.671

6.  Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia.

Authors:  Thiago Lisboa; Stijn Blot; Grant W Waterer; Emili Canalis; Diego de Mendoza; Alejandro Rodriguez; Jordi Rello
Journal:  Chest       Date:  2008-08-08       Impact factor: 9.410

7.  The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study.

Authors:  José Bordón; Paula Peyrani; Guy N Brock; Francesco Blasi; Jordi Rello; Thomas File; Julio Ramirez
Journal:  Chest       Date:  2008-01-15       Impact factor: 9.410

8.  PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia.

Authors:  Jordi Rello; Alejandro Rodriguez; Thiago Lisboa; Miguel Gallego; Manel Lujan; Richard Wunderink
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

9.  Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores.

Authors:  Mauricio Valencia; Joan R Badia; Manuela Cavalcanti; Miquel Ferrer; Carles Agustí; Joaquin Angrill; Elisa García; Josep Mensa; Michael S Niederman; Antoni Torres
Journal:  Chest       Date:  2007-05-15       Impact factor: 9.410

10.  Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

Authors:  Pierre-François Laterre; William L Macias; Jonathan Janes; Mark D Williams; David R Nelson; Amand R J Girbes; Jean-François Dhainaut; Edward Abraham
Journal:  Crit Care       Date:  2008-09-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.